In agreement, 1.2 mg of liraglutide was shown to prevent a weight loss–induced decrease in whole-body bone mineral content during 1 year after diet-induced weight loss in women with obesity.12 The finding that whole-body BMD, mostly reflecting cortical bone mass,51 increased with liraglutide, is in line with the observation of cortical osteopenia and fragility in GLP-1 receptor knockout mice.52,53 Interestingly, in the present study, exercise alone and in combination with liraglutide was associated with mostly preserved cortical bones (forearm) and more trabecular bones (hip and spine). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.